Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 5/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21551527 | 1.00 | SLC16A3 (0.59) | SLC16A3KCNH2KDM4ETSHRHSD17B10 | |
| SCHEMBL21550478 | 0.87 | SLC16A3 (0.62) | SLC16A3KCNH2KDM4ETSHRHSD17B10 | |
| SCHEMBL21550479 | 0.87 | SLC16A3 (0.62) | SLC16A3KCNH2KDM4ETSHRHSD17B10 | |
| SCHEMBL29637406 | 0.87 | SLC16A3 (0.62) | SLC16A3KCNH2KDM4ETSHRHSD17B10 | |
| SCHEMBL29725211 | 0.87 | SLC16A3 (0.56) | SLC16A3KCNH2KDM4ETSHRHSD17B10 | |
| SCHEMBL21551410 | 0.87 | SLC16A3 (0.56) | SLC16A3KCNH2KDM4ETSHRHSD17B10 | |
| SCHEMBL23116281 | 0.85 | SLC16A3 (0.61) | SLC16A3KCNH2KDM4ETSHRHSD17B10 | |
| SCHEMBL21565558 | 0.85 | SLC16A3 (0.61) | SLC16A3KCNH2KDM4ETSHRHSD17B10 | |
| SCHEMBL21551671 | 0.85 | SLC16A3 (0.58) | SLC16A3KCNH2KDM4ETSHRHSD17B10 | |
| SCHEMBL21551673 | 0.85 | SLC16A3 (0.58) | SLC16A3KCNH2KDM4ETSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| CN-115028637-B | Triazolopyrimidine compounds and their use for the treatment of cancer | 迪哲(江苏)医药股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11851432-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-12-26 | — | — | US | disclosed |
| EP-4134368-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-15 | — | — | EP | disclosed |
| CN-115028637-A | Triazolopyrimidine compounds and their use for the treatment of cancer | 迪哲(江苏)医药股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115028636-A | Triazolopyrimidine compounds and their use for the treatment of cancer | 迪哲(江苏)医药股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-3790879-B1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-06-29 | — | — | EP | disclosed |
| CN-112469721-B | Triazolopyrimidine compounds and their use for the treatment of cancer | 迪哲(江苏)医药股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20210340150-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-11-04 | — | — | US | disclosed |
| US-11084827-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-20210087196-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-03-25 | — | — | US | disclosed |
| EP-3790879-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD (CN) | 2021-03-17 | — | — | EP | disclosed |
| CN-112469721-A | Triazolopyrimidine compounds and their use for the treatment of cancer | 迪哲(江苏)医药股份有限公司 | 2021-03-09 | — | — | CN | disclosed |
| WO-2019215316-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | ABCC4, ABCB1, SLC16A3 | SLC16A3 3/4885KCNH2 410/4885KDM4E 1071/4885 |
| US-11084827-B2 | Triazolopyrimidine compounds and their use in treating cancer | ABCC4, ABCB1, SLC16A3 | SLC16A3 3/4885KCNH2 410/4885KDM4E 1071/4885 |
| US-20210087196-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ABCC4, ABCB1, SLC16A3 | SLC16A3 3/4885KCNH2 410/4885KDM4E 1071/4885 |
| US-20210340150-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ABCC4, ABCB1, SLC16A3 | SLC16A3 3/4885KCNH2 410/4885KDM4E 1071/4885 |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ABCC4, ABCB1, SLC16A3 | SLC16A3 3/4885KCNH2 410/4885KDM4E 1071/4885 |
| US-11851432-B2 | Triazolopyrimidine compounds and their use in treating cancer | ABCC4, ABCB1, SLC16A3 | SLC16A3 3/4885KCNH2 410/4885KDM4E 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.